BACKGROUND: Delayed ischaemic neurological deficit (DID) following subarachnoid haemorrhage from aneurysm rupture (aSAH) is a serious complication and a major cause of mortality and morbidity. No empirical estimates of resource use and costs of patients with delayed ischaemic deficit compared to those without have been reported to date. METHODS: A detailed cost analysis of the UK National Health Service health care costs of DID was performed using resource use data from the International Subarachnoid Aneurysm Trial (ISAT) over the 24 months following haemorrhage. Resource use categories included direct health care and employment-related costs. A prognostic model of baseline predictors of DID and overall total health care costs was also constructed. RESULTS: Mean (standard deviation) total health care costs at 24 months follow-up were estimated to be pound sterling 28175 (pound sterling 26773) in the DID group and pound sterling 18805 (pound sterling 17287) in the no DID group, a significant difference (95 % confidence interval) of pound sterling 9370 (pound sterling 6880 to pound sterling 12516). This cost difference was driven by statistically significant differences on imaging and investigations, longer length of stay and higher cost of complications and adverse events experienced by patients with DID. Patients with DID also spent on average 62 days less in paid employment than patients without this complication. The prognostic model found CT Fisher grading, WFNS grade, aneurysm location and time from aSAH to intervention statistically significant baseline predictors of delayed ischaemic deficit. CONCLUSION: Patients who developed DID incurred substantially higher costs and a significantly slower resumption of employment than patients without at 24 months follow-up after aSAH.
BACKGROUND: Delayed ischaemic neurological deficit (DID) following subarachnoid haemorrhage from aneurysm rupture (aSAH) is a serious complication and a major cause of mortality and morbidity. No empirical estimates of resource use and costs of patients with delayed ischaemic deficit compared to those without have been reported to date. METHODS: A detailed cost analysis of the UK National Health Service health care costs of DID was performed using resource use data from the International Subarachnoid Aneurysm Trial (ISAT) over the 24 months following haemorrhage. Resource use categories included direct health care and employment-related costs. A prognostic model of baseline predictors of DID and overall total health care costs was also constructed. RESULTS: Mean (standard deviation) total health care costs at 24 months follow-up were estimated to be pound sterling 28175 (pound sterling 26773) in the DID group and pound sterling 18805 (pound sterling 17287) in the no DID group, a significant difference (95 % confidence interval) of pound sterling 9370 (pound sterling 6880 to pound sterling 12516). This cost difference was driven by statistically significant differences on imaging and investigations, longer length of stay and higher cost of complications and adverse events experienced by patients with DID. Patients with DID also spent on average 62 days less in paid employment than patients without this complication. The prognostic model found CT Fisher grading, WFNS grade, aneurysm location and time from aSAH to intervention statistically significant baseline predictors of delayed ischaemic deficit. CONCLUSION:Patients who developed DID incurred substantially higher costs and a significantly slower resumption of employment than patients without at 24 months follow-up after aSAH.
Authors: C Charpentier; G Audibert; F Guillemin; T Civit; X Ducrocq; S Bracard; H Hepner; L Picard; M C Laxenaire Journal: Stroke Date: 1999-07 Impact factor: 7.914
Authors: Jane Wolstenholme; Oliver Rivero-Arias; Alastair Gray; Andrew J Molyneux; Richard S C Kerr; Julia A Yarnold; Mary Sneade Journal: Stroke Date: 2007-11-29 Impact factor: 7.914
Authors: N J Solenski; E C Haley; N F Kassell; G Kongable; T Germanson; L Truskowski; J C Torner Journal: Crit Care Med Date: 1995-06 Impact factor: 7.598
Authors: Andrew J Molyneux; Richard S C Kerr; Ly-Mee Yu; Mike Clarke; Mary Sneade; Julia A Yarnold; Peter Sandercock Journal: Lancet Date: 2005 Sep 3-9 Impact factor: 79.321
Authors: Wessel E van der Steen; Eva L Leemans; René van den Berg; Yvo B W E M Roos; Henk A Marquering; Dagmar Verbaan; Charles B L M Majoie Journal: Neuroradiology Date: 2019-01-28 Impact factor: 2.804
Authors: Sanne M Dorhout Mees; Richard S Kerr; Gabriel J E Rinkel; Ale Algra; Andrew J Molyneux Journal: J Neurol Date: 2011-09-24 Impact factor: 4.849
Authors: Juliette C Thompson; François-Xavier Chalet; Eric J Manalastas; Neil Hawkins; Grammati Sarri; Darren A Talbot Journal: Neurol Ther Date: 2022-04-20